FORT LAUDERDALE, Fla., Nov. 24 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer in laser optical breast imaging systems, is pleased to announce the issuance of its 21st US Patent entitled "Apparatus and Method for Acquiring Time-Resolved Measurements Utilizing Direct Digitization of the Temporal Point Spread Function of the Detected Light," dated November 4, 2008.
This invention, conceived by Steven Ponder Ph.D./Director of Advanced Development and Robert Wake/Vice President of Engineering for Imaging Diagnostic Systems, covers a key technology for time-resolved optical imaging which improves the quality of the imaging data and decreases the time required to acquire the image data.
This invention exploits a long-established trend in integrated circuit evolution to advance the acquisition of time-resolved image data for optical imaging of human and animal subjects.
"Time-resolved CTLM imaging of the breast can provide quantitative information that may be used to discriminate between malignant and benign lesions. However, the technique is inherently more time consuming than our standard continuous wave Computed Tomography Laser Mammography (CTLM) scanning method, and it requires sophisticated and expensive circuitry to make accurate measurements of the very short pulses of light used in time-resolved imaging. This invention exploits recent advances in the speed of digital acquisition components in order to reduce the cost and complexity of time-resolved measurement systems," stated Dr. Ponder
This invention will also reduce the costs of what has been an otherwise prohibitively expensive technology, namely efficient time-resolved optical imaging, whether computed tomography or topography.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM(R) system is a patented new breast imaging system that utilizes state of the art laser technology and patented algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM(R)) is designed to be used in conjunction with mammography in detecting breast cancer in the dense breast patient population, which is not commonly detected with mammography alone.
Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM(R)) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.
For more information, visit our corporate website: www.imds.com
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
Imaging Diagnostic Systems
|SOURCE Imaging Diagnostic Systems, Inc.|
Copyright©2008 PR Newswire.
All rights reserved